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Absolute stereochemistry of oils and viscous liquids can be 
difficult to determine. Co-crystallization involves 
generating a crystalline material consisting of more than 
one neutral compound. The combination of co-
crystallization with both X-ray diffraction and chiral HPLC 
was particularly powerful in overcoming these difficulties 
for a series of chiral 3-arylbutanoic acids. Co-
crystallization offers advantages over salt formation 
because co-crystals dissociate in solution, meaning 
identical HPLC conditions can be used for both the 
materials of interest and their co-crystals. 
 
Despite major advances in asymmetric synthesis over the 
past thirty years,
1
 one of the major challenges which remains 
is definitively assigning absolute stereochemistry,
2
 especially 
with materials which are not readily crystalline. This is 
increasingly important as new synthetic products are often 
difficult to crystallise,
3
 and many can only be isolated as 
viscous oils. 
The two main synthetic strategies which have been 
employed to circumvent these problems involve modification 
of the material, via either additional chemical transformations 
or salt formation.
4
 Both of these strategies, however, have 
limitations. The use of chemical transformations can be 
limited by the availability of only small quantities of 
enantiopure material, and furthermore, additional reaction 
steps may affect the stereochemical integrity of the required 
compound. For salt formation, in addition to the limitations 
mentioned above, the compound also requires ionizable sites. 
For both strategies, chiral HPLC analysis has to be developed 
not only for the pure material but also for the derivatives, 
since in many cases the conditions are non-transferrable.
4
 
As part of an on-going program of research into 
enantioselective biotransformations, we have been interested 
in determining the absolute stereochemistry of a series of 
substituted 3-arylbutanoic acids 1a–1d, obtained via 
enzymatic hydrolysis of the corresponding ethyl ester (Figure 
1).
5
 The enantiopure products were isolated as liquids at room 
temperature. The enantioselectivity of the enzyme catalyzed 
reactions was investigated by chiral HPLC analysis,
5
 and 
appropriate conditions to separate and quantify the 
enantiomers of 1a–1d were identified. However, knowledge 
of absolute stereochemistry was necessary to determine the 
sense of enantioselection with each of the biocatalysts 
employed. Chemical transformations were not attempted, as 
the enantiopure samples were available in limited quantities. 
 
 
 
Figure 1. The enzymatic biotransformation employed in this work.
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Co-crystallization, involving crystallizing two (or more) 
neutral molecules together in one crystalline material, has 
recently garnered great interest as an alternative to salt 
formation for improving the physical properties of active 
pharmaceutical ingredients, without detrimental effects on the 
chemical properties.
6
 Therefore, we decided to investigate if 
co-crystals involving the carboxylic acids 1a–1d would be 
suitable materials for determining their absolute 
stereochemistry. 
A search of the Cambridge Structural Database
7
 revealed 
that monocarboxylic acids often co-crystallize with 
nicotinamide and isonicotinamide.
8-10
 Initial co-crystal 
screening was performed by neat grinding with the racemic 
acid, and isonicotinamide was identified by powder X-ray 
diffraction (see Supporting Information) as a suitable co-
crystal former for each of the acids (Figure 2). 
 
 
Figure 2. Co-crystallization of the 3-arylbutanoic acids with 
isonicotinamide. 
 
  
2  
Suitable conditions for growing single crystals from 
solution were identified using the racemic acids and similar 
conditions were applied to the enantiopure analogs. The 
advantage of this approach was that once the conditions were 
developed, a small sample of the enantiopure material (< 8 
mg) was sufficient. All co-crystals, both enantiopure and 
racemic, were grown by slow evaporation of acetonitrile : 
acetone (70 : 30) solutions. 
Single crystal diffraction data, in combination with the 
chromatographic experiments, allowed the unambiguous 
assignment of absolute configuration.
11
 Each enantiopure co-
crystal was formed with the (S)-enantiomer of the acid. Each 
of the co-crystals display a common set of intermolecular 
interactions (Figures 3 and 4) with amide-amide [N-H...O=C] 
and acid-pyridine [COOH...N] hydrogen bonds linking the co-
crystal components. 
 
 
 
Figure 3. Hydrogen bonding interactions in (S)-2a. The different 
colors indicate unique, symmetry-independent (S)-2a (green and blue) 
and isonicotinamide (red and orange) molecules. The same motif is 
formed in (S)-2c, (S)-2d, (±)-2b and (±)-2c, see Supporting 
Information. 
 
 
 
Figure 4. Hydrogen bond motif in (S)-2b. The same color scheme is 
applied as for Figure 1. 
 
Interestingly, irrespective of the chiral or enantiopure nature 
of the acid molecules, similar infinite one-dimensional 
hydrogen-bonded ribbons are formed in all the co-crystals 
except (±)-2d, which exhibits two-dimensional puckered 
sheets (see Supporting Information). Thus, the overall core 
hydrogen-bonded motif is retained across the structures, with 
the conformation of the acids varying. Presumably, this 
conformational variation is necessary to maintain both a close-
packed arrangement of molecules with asymmetric shapes and 
a (topologically) symmetrical hydrogen bond network. Further 
details of the structural features present in these co-crystals are 
in the Supporting Information. 
An important consideration was whether the diffraction 
experiment was a true representation of the bulk sample. To 
ensure this was the case, powder X-ray diffraction, PXRD, 
was performed on each of the ground materials 2a–2d and 
compared to the theoretical PXRD patterns calculated from 
the single crystal data. 
We anticipated that acid molecules, once dissolved, would 
have the same properties irrespective of whether they are 
obtained by dissolving the pure acid or the co-crystal, as co-
crystallization only affects the properties of the solid phase. 
Thus, co-crystallization has the clear advantage that the 
conditions developed to separate the enantiomers of the pure 
compound by chiral HPLC can be applied directly for analysis 
of the co-crystal employed for X-ray crystallography, enabling 
direct correlation with the chiral HPLC peak for the 
enantiomer. The only potential concern is the impact of the 
co-crystal former. To check for possible interference, chiral 
HPLC of the racemic acids, in the presence of 
isonicotinamide, was recorded, clearly showing that 
chromatographic behavior of 1a–1d was unaffected, 
confirming the validity of the methodology employed. Thus, 
chiral HPLC were recorded on the individual crystals used for 
the X-ray diffraction experiments. This enabled the use of 
chiral HPLC to directly monitor the direction of 
enantioselection in the enzyme mediated resolutions, Figure 
5.
5
 Thus, while (S)-1a has been previously described in the 
literature,
12
 this is the first time the absolute stereochemistry of 
this compound has been definitively determined by X-ray 
diffraction. This procedure was successfully employed to 
determine the absolute stereochemistry of the novel 
enantiopure acids (S)-1b–1d. 
 
 
 
 
Figure 5. Chiral HPLC trace for (±)-1b, top; (±)-2b, middle; and (S)-
2b, bottom. For (±)-2b and (S)-2b, the data is obtained using the 
individual crystal from the single crystal analysis. 
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Co-crystallization involving achiral compounds with 
enantiopure and racemic partners is known; in particular 
interest has centred on the different physical properties that 
are obtained for the racemic and enantiopure co-crystals, such 
as density and stability.
8,13
 It has been used to introduce heavy 
atoms into a chiral structure, enabling absolute 
stereochemistry determination of known materials using 
Mo-K radiation.
14
 To date the stereochemistry of the starting 
material has always been known. 
Our results demonstrate for the first time that the 
application of co-crystallization methodology can be utilized 
successfully for determination of the absolute stereochemistry 
of compounds that are oils or viscous liquids at ambient 
conditions. The advantage of co-crystals over salt formation is 
that the chromatographic conditions developed to separate the 
enantiomers do not change on co-crystallization, unless the 
co-crystal former interferes with the separation of the 
enantiomers. Furthermore, co-crystals do not require ionizable 
sites, which in principle means that co-crystallization should 
be more universally applicable than salt formation. In 
conclusion, co-crystallization and X-ray diffraction, in 
combination with chiral HPLC, provides an effective method 
in synthetic research to identify absolute stereochemistry in 
novel compounds. 
 
EXPERIMENTAL SECTION 
General Experimental. Compounds (±)-1a, (±)-1b, (±)-1c, 
(±)-1d, (S)-1a, (S)-1b, (S)-1c, (S)-1d were prepared according 
to the literature methods.
5
 Grinding was undertaken using a 
mixer mill equipped with stainless steel 5 mL grinding jars 
and one 2.5 mm stainless steel grinding ball per jar. Powder 
diffraction experiments were performed using graphite 
monochromatized Cu-K radiation at room temperature. 
Single crystal diffraction experiments were performed using 
either graphite monochromatized Mo-K or doubly curved 
silicon crystal monochromatized Cu-K radiation at 100 K. 
Analysis was undertaken using the SHELX suite of 
programs
15
 and diagrams prepared with Mercury 2.3.
16
 
Differential Scanning Calorimetry was undertaken over the 
temperature range 40 – 140 C and the sample was heated at a 
rate of 4 C min
-1
. Chiral HPLC analysis was undertaken using 
a chiral column (Chiralcel OJ-H for 2a, 2b, and 2c, Chiralcel 
AS-H for 2d) at 0 C. 
General Procedure for Preparation of the Racemic Acid 
: Isonicotinamide Co-crystals. The corresponding racemic 
acid (1 equiv) and isonicotinamide (1 equiv) were placed in 
the grinding jars, and the mill was operated at 30 Hz for 30 
min. The material obtained was analyzed by PXRD. It was 
then dissolved in a minimum amount of acetonitrile and 
acetone added until the solvent ratio was 70 : 30 respectively. 
The solution was allowed to stand at ambient conditions and 
crystals suitable for single crystal diffraction were obtained by 
slow evaporation over 3-4 d. After single crystal analysis, 
chiral HPLC analysis was performed on the actual crystal used 
in the diffraction experiment. 
Synthesis of (±)-3-o-tolylbutanoic acid : isonicotinamide 
co-crystal, (±)-2b. Isonicotinamide (27 mg, 0.22 mmol) and 
(±)-1b (40 mg, 0.22 mmol) were used; mp 84 – 86 C. Crystal 
data: C17H20N2O3, M = 300.35, triclinic, a = 9.6495(16) Å, b = 
12.915(2) Å, c = 13.390(2) Å, α = 102.007(3)°, β = 
103.616(4)°, γ = 92.047(4)°, V = 1580.0(4) Å
3
, T = 100.(2) K, 
space group P1¯ , Z = 4, 43120 reflections measured, 7818 
unique (Rint = 0.0647). The final R1 values were 0.0402 (I > 
2σ(I)) and 0.0570 (all data). The final wR(F
2
) values were 
0.1009 (I > 2σ(I)) and 0.1070 (all data). HPLC data: Chiralcel 
OH-J, eluent hexane : i-PrOH (3% trifluoroacetic acid), 94 : 6, 
flow rate 0.25 mLmin
-1
,  = 209.8 nm, RT (min): S = 33.1 and 
R = 62.7. 
General Procedure for Preparation of the Enantiopure 
Acid : Isonicotinamide Co-crystals. The corresponding 
enantiopure acid (1 equiv) and isonicotinamide (1 equiv) were 
treated in an identical fashion to the racemic compounds, 
except the initial grinding and subsequent PXRD analysis 
steps were omitted. 
Synthesis of (S)-3-o-tolylbutanoic acid : isonicotinamide 
co-crystal, (S)-2b. Isonicotinamide (5 mg, 0.06 mmol) and 
(S)-1b (7 mg, 0.05 mmol) were used; mp 89 – 91 C. Crystal 
data: C17H20N2O3, M = 300.35, triclinic, a = 7.1279(4) Å, b = 
8.8202(5) Å, c = 13.1405(8) Å, α = 102.542(3)°, β = 
92.659(3)°, γ = 95.430(3)°, V = 800.90(8) Å
3
, T = 100.(2) K, 
space group P1, Z = 2, 18797 reflections measured, 5028 
unique (Rint = 0.0238). The final R1 values were 0.0278 (I > 
2σ(I)) and 0.0285 (all data). The final wR(F
2
) values were 
0.0773 (I > 2σ(I)) and 0.0781 (all data). Flack parameter = -
0.10(9), Hooft y parameter = 0.05(6). HPLC data: Chiralcel 
OH-J, eluent hexane : i-PrOH (3% trifluoroacetic acid), 94 : 6, 
flow rate 0.25 mLmin
-1
,  = 209.8 nm, RT (min): S = 32.7. 
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